Empasiprubart clinical trials
Also written ARGX-117.
How each study uses empasiprubart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the empasiprubart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2026 (5)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5, 2 in phase 3
Studies that test empasiprubart, phase 3 first.
- Sep 2027A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPPhase 3 · argenx
- Oct 2027A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPPhase 3 · argenx
- Nov 2026A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With DermatomyositisPhase 2 · argenx
- Mar 2027A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult ParticipantsPhase 1 · argenx
- Oct 2027ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia GravisPhase 2 · argenx
Studies
Open first, then newest update. How each study uses empasiprubart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPRecruitingPhase 3argenxNCT06920004Written as empasiprubart
- A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor NeuropathyRecruitingPhase 1argenxNCT07610564Written as Empasiprubart IV
- A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPRecruitingPhase 3argenxNCT07091630Written as Empasiprubart IV
- ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia GravisRecruitingPhase 2argenxNCT07673627Written as Empasiprubart IV
- A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré SyndromeNot yet recruitingPhase 2argenxNCT07821762Written as Empasiprubart IV
- A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult ParticipantsRecruitingPhase 1argenxNCT07612020Written as empasiprubart IV
- A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating PolyradiculoneuropathyWithdrawnPhase 2/3argenxNCT07638566Written as Empasiprubart IV
- A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With DermatomyositisActive, not recruitingPhase 2argenxNCT06284954Written as Empasiprubart IV
- ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft FunctionActive, not recruitingPhase 2argenxNCT05907096Written as ARGX-117
- A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor NeuropathyActive, not recruitingPhase 3argenxNCT06742190Written as Empasiprubart
- A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor NeuropathyCompletedPhase 2argenxNCT05225675Written as ARGX-117
- A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor NeuropathyActive, not recruitingPhase 2argenxNCT05405361Written as ARGX-117
- SAD and MAD Study With IV and SC Doses of ARGX-117CompletedPhase 1argenxNCT04532125Written as ARGX-117
Given beside what is tested · 1 — empasiprubart is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Codes
What other systems call empasiprubart · ClinicalTrials.gg INT017616
- UNII (FDA) PVA73UA67LEMPASIPRUBARTOne source FDA
- NCI Thesaurus C190478EmpasiprubartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | PVA73UA67L | EMPASIPRUBART | One source FDA |
| NCI Thesaurus | C190478 | Empasiprubart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.